WASHINGTON – The Association for Accessible Medicines today commented on the announcement by Amphastar Pharmaceuticals, Inc. to invest in domestic manufacturing and quadruple their production in the next three to five years.
“Amphastar’s largest investment in company history focused exclusively on domestic manufacturing and supply chain resilience is yet another proof point that AAM member companies are focused on the U.S. health care system and patients,” said John Murphy III, President and CEO of AAM. “While our members work to develop investment and expansion plans to serve the growing needs of American patients, AAM will be working alongside legislators and regulators to pursue reforms to the U.S. market with an eye towards ending brand company patent and rebate games, enhancing reimbursement and access to foster generics-first patient access, shining a light on consolidation in the GPO and PBM markets that distort incentives and inhibit access to affordable medicines, and overall pursuing policies that can sustain and grow this market in the long term.”
Amphastar Pharmaceuticals is a focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products. Yesterday, they announced a multi-year expansion of its U.S. manufacturing operations in California. The company plans to quadruple its production capacity over the next three to five years, reinforcing its commitment to domestic pharmaceutical manufacturing and strengthening supply chain resilience.
Amphastar’s expansion is their largest investment in domestic infrastructure in company history. This will feature a new state-of-the-art production plant, expanded automation, and the integration of advanced technologies to support the development and manufacture of critical medications, including supporting the production of new pipeline candidates. The company expects to create new jobs in research and development, engineering, manufacturing, and quality operations upon completion.
